Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia

ConclusionTaken together, desidustat is well absorbed orally. It showed a dose-dependent increase in exposure, did not accumulate in tissue, and was eliminated via dual routes. It is metabolically stable, has minimal potential to cause clinical drug –drug interactions (DDIs), and demonstrates discriminable pharmacokinetic properties for the treatment of anemia.

http://rd.springer.com/10.1007/s13318-022-00788-3

Source: European Journal of Drug Metabolism and Pharmacokinetics - July 26, 2022 Category: Drugs & Pharmacology Source Type: research